Form 8-K · Current Report · Filed 2024-09-12
Moderna Announces R&D Updates and Financial Framework Extension
Moderna, Inc. announced program and financial updates at its annual R&D Day event on September 12, 2024. The Company expects to submit three respiratory vaccines for approval in 2024 and announced positive Phase 3 results for its RSV and standalone flu vaccines. Moderna also presented its strategic prioritization of its mRNA pipeline and expects to reduce annual research and development expense by approximately $1.1 billion starting in 2027. Additionally, the Company updated its financial framework through 2028.
- Filer
- Moderna Inc. MRNA · NASDAQ
- Filed
- Accession
- 0001682852-24-000049
- CIK
- 0001682852
- Signal
- Low impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Regulation FD Disclosure
Financial Statements and Exhibits
Market reaction
Close before filing
$79.51
Next session
-14.1%
Since filing
-31.1%
Latest close
$54.82
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from MRNA reporting the same item, with the next session's move:
Exhibits (1)
About Moderna Inc.
Moderna Inc. is a biotechnology company focused on developing transformative medicines based on messenger RNA (mRNA) technology. Its primary function is to research and produce a broad spectrum of vaccines and therapeutics by leveraging its proprietary mRNA technology platform. Moderna is notably recognized for its pivotal role in the healthcare and pharmaceutical sector, particularly due to its development of one of the first COVID-19 vaccines to receive emergency use authorization. The company’s pipeline extends beyond infectious diseases, targeting therapeutic areas such as oncology, cardiovascular diseases, and rare genetic disorders. Headquartered in Cambridge, Massachusetts, Moderna takes a leading position in the biotechnology industry through its innovative approach to drug development, emphasizing rapid advancement from concept to clinical application. The company plays a crucial role in addressing global health challenges through its cutting-edge mRNA-based solutions.
Never miss another MRNA filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.